You have free access to this content

Cancer

Cover image for Cancer

15 February 2008

Volume 112, Issue 4

Pages 731–954

  1. Original Articles

    1. Top of page
    2. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients : A population-based study (pages 731–736)

      Ido Wolf, Noa Ben-Baruch, Ronnie Shapira-Frommer, Shulamit Rizel, Hadassa Goldberg, Neora Yaal-Hahoshen, Baruch Klein, David B. Geffen and Bella Kaufman

      Article first published online: 12 DEC 2007 | DOI: 10.1002/cncr.23225

      Recurrence score risk stratification and the association between the score and standard clinical and pathologic breast cancer characteristics may be different among referred patients compared with a clinical trial population. Among the referred patients, standard characteristics, as well as various clinical guidelines, failed to predict the recurrence score.

    2. You have free access to this content
      The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004 (pages 737–747)

      Monica Brown, Alex Tsodikov, Katrina R. Bauer, Carol A. Parise and Vincent Caggiano

      Article first published online: 11 JAN 2008 | DOI: 10.1002/cncr.23243

      Data from the California Cancer Registry were used to assess the relative contribution of human epidermal growth factor receptor 2 (HER2) to the survival of patients with invasive breast cancers that were negative for estrogen receptor (ER), progesterone receptor (PR) and HER2 (triple negative) compared with breast cancers that were negative for ER and PR but positive for HER2 (double negative) and all other breast cancers. The survival of patients with triple-negative breast cancers was very similar to that of patients with double-negative breast cancers, and the survival of both groups contrasted greatly with the survival of patients with other breast cancers. The authors observed that ER and PR negativity, rather than HER2, were the predominant factors contributing to poor survival.

    3. You have free access to this content
      Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer : The Rotterdam Study (pages 748–757)

      Ronald van der Knaap, Claire Siemes, Jan-Willem W. Coebergh, Cornelia M. van Duijn, Albert Hofman and Bruno H. Ch. Stricker

      Article first published online: 7 JAN 2008 | DOI: 10.1002/cncr.23215

      The angiotensin I-converting enzyme (ACE) gene insertion/deletion polymorphism has been associated with breast cancer. The objective of the current study was to determine whether antihypertensive drugs that act on the renin-angiotensin system can decrease cancer risk in individuals who have the high-activity ACE genotype DD.

    4. You have free access to this content
      Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI) (pages 758–766)

      Frank Vicini, Peter D. Beitsch, Coral A. Quiet, Angela J. Keleher, Delia Garcia, Howard C. Snider Jr, Mark A. Gittleman, Victor J. Zannis, Henry M. Kuerer and Maureen Lyden

      Article first published online: 7 JAN 2008 | DOI: 10.1002/cncr.23227

      Treatment efficacy, cosmesis, and toxicity 3 years after treatment with accelerated partial breast irradiation (APBI) using the MammoSite device are good and similar to those reported with other forms of APBI with similar follow-up.

    5. Gastrointestinal Disease
      You have free access to this content
      GABAB receptor is a novel drug target for pancreatic cancer (pages 767–778)

      Hildegard M. Schuller, Hussein A. N. Al-Wadei and Mourad Majidi

      Article first published online: 20 DEC 2007 | DOI: 10.1002/cncr.23231

      Stimulation of the GABAB receptor blocked isoproterenol-induced cAMP signaling, ERK1/2 activity, cell proliferation and cell migration in human pancreatic cancer cell lines and pancreatic duct epithelia. Pancreatic cancers overexpressed norepinephrine and PKARIIα while underexpressing GABA. The findings suggest that GABABR agonists may provide a novel tool for the treatment and prevention of pancreatic cancer.

    6. You have free access to this content
      Cost-effectiveness of targeted and tailored interventions on colorectal cancer screening use (pages 779–788)

      David R. Lairson, Melissa DiCarlo, Ronald E. Myers, Thomas Wolf, James Cocroft, Randa Sifri, Michael Rosenthal, Sally W. Vernon and Richard Wender

      Article first published online: 20 DEC 2007 | DOI: 10.1002/cncr.23232

      Mailed stool blood tests significantly boosted colorectal cancer screening use, and the intervention was well within the range of acceptable cost compared with other practice-based studies of colorectal cancer screening promotion. Although a tailored intervention plus telephone call reminder was more effective than a targeted intervention, it was not an economically attractive strategy.

    7. You have free access to this content
      Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population (pages 789–799)

      Sharon A. Dobie, Joan L. Warren, Barbara Matthews, David Schwartz, Laura-Mae Baldwin and Kevin Billingsley

      Article first published online: 11 JAN 2008 | DOI: 10.1002/cncr.23244

      Compared with elderly stage II patients, elderly stage III rectal cancer patients are more likely to complete adjuvant radiation and chemotherapy. Both groups had lower cancer-related mortality than other same-stage patients in the cohort only if they completed both adjuvant radiation and chemotherapy.

    8. Genitourinary Disease
      You have free access to this content
      The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor (pages 800–805)

      Atreya Dash, Brett S. Carver, Jason Stasi, Dean F. Bajorin, Robert J. Motzer, George J. Bosl and Joel Sheinfeld

      Article first published online: 2 JAN 2008 | DOI: 10.1002/cncr.23233

      The authors investigated the clinical outcome, patterns of relapse, and incidence of teratoma in the retroperitoneum for men with clinical stage IS (cIS) nonseminomatous germ cell tumor (NSGCT). The results indicated that patients with cIS NSGCT benefit from adjuvant postchemotherapy retroperitoneal lymph node dissection.

    9. You have free access to this content
      Hospital lymph node counts and survival after radical cystectomy (pages 806–812)

      Brent K. Hollenbeck, Zajoun Ye, Sandra L. Wong, James E. Montie and John D. Birkmeyer

      Article first published online: 17 DEC 2007 | DOI: 10.1002/cncr.23234

      Hospitals with high lymph node counts tend to have higher survival rates after radical cystectomy for bladder cancer. However, this effect is more modest than that appreciated in patient-level studies, and is explained, in large part, by confounding patient and hospital factors.

    10. You have free access to this content
      The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate (pages 813–819)

      Gabriel Sandblom, Sam Ladjevardi, Hans Garmo and Eberhard Varenhorst

      Article first published online: 20 DEC 2007 | DOI: 10.1002/cncr.23235

      In a large cohort of men with localized prostate tumors detected from a population in which screening scarcely was performed, an inverse correlation between relative survival and prostate-specific antigen (PSA) level was observed among men with a PSA level <4 ng/mL. This most likely can be explained by a relative predominance of men who had undifferentiated tumors, which do not secrete PSA, in this group.

    11. Gynecologic Oncology
      You have free access to this content
      Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas : Emphasis on impact of lymphadenectomy and oophorectomy (pages 820–830)

      Daniel S. Kapp, Jacob Y. Shin and John K. Chan

      Article first published online: 11 JAN 2008 | DOI: 10.1002/cncr.23245

      This results from this analysis indicated that independent predictors of disease-specific survival in patients with uterine leiomyosarcoma included age, race, disease stage, tumor grade, and primary surgery.

    12. Hematologic Malignancies
      You have free access to this content
      Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma (pages 831–836)

      Yasuhiro Oki, Barbara Pro, Luis E. Fayad, Jorge Romaguera, Felipe Samaniego, Fredrick Hagemeister, Sattva Neelapu, Peter McLaughlin, Andre Goy and Anas Younes

      Article first published online: 17 DEC 2007 | DOI: 10.1002/cncr.23237

      Thirty-three patients with recurring or refractory Hodgkin lymphoma were treated with combination therapy using gemcitabine and rituximab, demonstrating an overall response rate of 48%. The activity and favorable safety profile warrant investigating this regimen further in combination with other active drugs.

    13. You have free access to this content
      Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia : Need for new response definitions? (pages 837–845)

      Hagop Kantarjian, Susan O'Brien, Jianqin Shan, Xuelin Huang, Guillermo Garcia-Manero, Stefan Faderl, Farhad Ravandi-Kashani, Srdan Verstovsek, Mary Beth Rios and Jorge Cortes

      Article first published online: 17 DEC 2007 | DOI: 10.1002/cncr.23238

      The study compared the standard definition of cytogenetic response to imatinib therapy (single-time best response) in chronic myeloid leukemia to response at treatment intervals and durable responses. The incidence of complete cytogenetic response (CGCR) as single-time best response was 91%, but the incidence of CGCR at 4 years was only 78%. The incidence of major molecular response was 74% as best single-time event versus 62% at 4 years; the incidence of undetectable BCR-ABL transcripts was 38% versus 24%. There was a strong association between achieving cytogenetic and molecular response at landmark times (6 and 12 months) with survival and progression-free survival. Results of future studies using the landmark responses in addition to best single-time response will need to be presented.

    14. You have free access to this content
      Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation (pages 846–855)

      Delphine Sénécal, Jean-Philippe Jais, Bernard Desablens, Christian Berthou, Philippe Casassus, Marie-Pierre Moles, Vincent Delwail, Thomas Gastinne, Pierre Colonna and Jean-Marie Andrieu

      Article first published online: 10 DEC 2007 | DOI: 10.1002/cncr.23247

      The 20-year results of 2 prospective studies applied to 213 patients with Hodgkin lymphoma at clinical stages IIIB and IV were analyzed. Treatment consisted of 3 cycles of doxorubicin (adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) or ABVD-like chemotherapy and extended high-dose radiation. The overall survival was found to be identical to that observed after 6 to 8 cycles of ABVD (without radiotherapy). The disease-specific survival rate (82%) was stable from the 12th year after treatment onward, whereas the freedom from treatment-related mortality (resulting mainly from extended high-dose radiation) was 66% by 20 years (without reaching a plateau).

    15. You have free access to this content
      A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma (pages 856–862)

      Pier Luigi Zinzani, Monica Tani, Stefano Fanti, Vittorio Stefoni, Gerardo Musuraca, Umberto Vitolo, Alessio Perrotti, Mariapaola Fina, Enrico Derenzini and Michele Baccarani

      Article first published online: 11 JAN 2008 | DOI: 10.1002/cncr.23236

      In this study, the authors established the feasibility, tolerability, and efficacy of fludarabine plus mitoxantrone followed by yttrium-90 ibritumomab tiuxetan patients with untreated, indolent, nonfollicular non-Hodgkin lymphoma.

    16. Lung Disease
      You have free access to this content
      Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16 cells and display an impaired capability to kill tumor cells (pages 863–875)

      Paolo Carrega, Barbara Morandi, Roberta Costa, Guido Frumento, Giuseppe Forte, Giuseppe Altavilla, Giovanni Battista Ratto, Maria Cristina Mingari, Lorenzo Moretta and Guido Ferlazzo

      Article first published online: 17 JAN 2008 | DOI: 10.1002/cncr.23239

      Limited information is available on natural killer (NK) cells infiltrating malignant tumors, especially in humans, thus precluding the development of rational NK cell-based therapeutic attempts. This study characterized NK cells infiltrating nonsmall cell lung cancer for the first time and shows that they are mainly capable of producing relevant cytokines rather than exerting direct cancer cell killing.

    17. You have free access to this content
      From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer (pages 876–884)

      Branislav Jeremić and Biljana Miličić

      Article first published online: 2 JAN 2008 | DOI: 10.1002/cncr.23240

      Patients with early-stage nonsmall cell lung cancer who received either conventionally fractionated (CF) radiation therapy (RT), or hyperfractionated (HFX) RT, or HFX RT with concurrent paclitaxel plus carboplatin (HFX RT-Pac/C) were reviewed. CF RT was significantly inferior to either HFX RT alone or HFX RT-Pac/C; however, the latter regimen had a higher incidence of acute high-grade hematologic toxicity.

    18. Neuro-Oncology
      You have free access to this content
      Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma : A retrospective analysis of 12 cases (pages 885–891)

      Naomi Kiyota, Makoto Tahara, Satoshi Fujii, Mitsuhiko Kawashima, Takashi Ogino, Hironobu Minami, Ryuichi Hayashi and Atsushi Ohtsu

      Article first published online: 11 JAN 2008 | DOI: 10.1002/cncr.23246

      Chemotherapy with irinotecan plus docetaxel for olfactory neuroblastoma was safe and manageable. Induction chemotherapy followed by definitive radiotherapy may represent a promising option for locally advanced olfactory neuroblastoma.

    19. You have free access to this content
      Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma : A Canadian Pediatric Brain Tumor Consortium experience (pages 892–899)

      Lucie Lafay-Cousin, Lillian Sung, Anne-Sophie Carret, Juliette Hukin, Beverly Wilson, Donna L. Johnston, Shayna Zelcer, Mariana Silva, Isaac Odame, Chris Mpofu, Douglas Strother and Eric Bouffet

      Article first published online: 20 DEC 2007 | DOI: 10.1002/cncr.23249

      Carboplatin hypersensitivity reaction (Cb HSR) represents a common and limiting factor for the continuation of therapy in children with low-grade glioma. In this report, the authors described the prevalence, characteristics, and management of Cb HSR and its impact on patient outcomes.

    20. Discipline

      Cancer Disparities
      You have free access to this content
      Racial disparities in cancer therapy : Did the gap narrow between 1992 and 2002? (pages 900–908)

      Cary P. Gross, Benjamin D. Smith, Elizabeth Wolf and Martin Andersen

      Article first published online: 7 JAN 2008 | DOI: 10.1002/cncr.23228

      Racial disparities in cancer care persisted throughout the period 1992–2002. These disparities were present across numerous cancer types and were moderated by socioeconomic status. Efforts in the last decade to mitigate cancer therapy disparities appear to have been unsuccessful.

    21. You have free access to this content
      Geographic access to cancer care in the U.S. (pages 909–918)

      Tracy Onega, Eric J. Duell, Xun Shi, Dongmei Wang, Eugene Demidenko and David Goodman

      Article first published online: 11 JAN 2008 | DOI: 10.1002/cncr.23229

      Geographic access to the most specialized cancer care is limited for Native Americans, nonurban populations, and residents in the South of the U.S. Travel time to the nearest National Cancer Institute Cancer Center is >1 hour for 55% of the U.S. population.

    22. Epidemiology
      You have free access to this content
      Fatherhood status and prostate cancer risk (pages 919–923)

      Kristian T. Jørgensen, Bo V. Pedersen, Christoffer Johansen and Morten Frisch

      Article first published online: 7 JAN 2008 | DOI: 10.1002/cncr.23230

      The issue of whether fatherhood status affects the risk of prostate cancer remains controversial. Recently, it was proposed that childless men are at lower risk of prostate cancer than men with children and that men with sons may be at lower risk than men with daughters only. The findings of the current study indicate that childless men and men with many children are at a reduced risk of prostate cancer.

    23. Pathology
      You have free access to this content
      Histopathologic determinants of regional lymph node metastasis in early colorectal cancer (pages 924–933)

      Yukio Ishikawa, Yuri Akishima-Fukasawa, Kinji Ito, Yoshikiyo Akasaka, Tomoko Yokoo, Toshiharu Ishii and and the Toho Study Group for Cancer Biological Behavior

      Article first published online: 7 JAN 2008 | DOI: 10.1002/cncr.23248

      Colorectal tissues from 71 patients with early colorectal cancer were immunostained with lymphatic endothelial hyaluronan receptor 1, β-catenin, claudin-3, claudin-4, and cytokeratin antibodies. Only 2 factors, lymphatic invasion and budding formation at the invasive front, were identified as independent predictors of lymph node metastasis.

    24. Quality of Life
      You have free access to this content
      Understanding high-quality cancer care : A summary of expert perspectives (pages 934–942)

      Erin J. Aiello Bowles, Leah Tuzzio, Cheryl J. Wiese, Beth Kirlin, Sarah M. Greene, Steven B. Clauser and Edward H. Wagner

      Article first published online: 7 JAN 2008 | DOI: 10.1002/cncr.23250

      The Institute of Medicine report Crossing the Quality Chasm proposed 6 aims for high-quality healthcare: effective, safe, timely, efficient, equitable, and patient-centered, and emphasized care coordination. In the current study, nationally recognized experts shared ideas on barriers (notably lack of standardization and guidelines) and facilitators (including increased use of information technology) to high-quality cancer care.

    25. Radiation Oncology
      You have free access to this content
      External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis (pages 943–949)

      Karen E. Hoffman, Theodore S. Hong, Anthony L. Zietman and Anthony H. Russell

      Article first published online: 20 DEC 2007 | DOI: 10.1002/cncr.23241

      The effect of incidental radiation exposure during rectal cancer treatment on subsequent prostate cancer diagnosis was investigated using the Surveillance, Epidemiology, and End Results (SEER) cancer registry. External beam radiation therapy for rectal cancer was associated with a 72% decrease in the frequency of subsequent prostate cancer diagnosis compared with men in the general population of similar age and race. Potential explanations for this observation are discussed.

    26. Symptom Control and Palliative Care
      You have free access to this content
      Manipulative therapy of secondary lymphedema in the presence of locoregional tumors (pages 950–954)

      Ximena A. Pinell, Stephanie H. Kirkpatrick, Kennedy Hawkins, Tammy E. Mondry and Peter A. S. Johnstone

      Article first published online: 17 DEC 2007 | DOI: 10.1002/cncr.23242

      Patients with lymphedema may obtain relief with complete decongestive therapy regardless of whether they have locoregional disease contributing to their symptoms.

SEARCH

SEARCH BY CITATION